Japanese Regulatory Perspective on Immunogenicity-Reference-Cited by-同舟云学术

Japanese Regulatory Perspective on Immunogenicity

Published:2011-06-20 Issue: Volume: Page:57-79
ISSN:
Container-title:Detection and Quantification of Antibodies to Biopharmaceuticals
language:
Short-container-title:

Author:

Hayakawa Takao,Ishii-Watabe Akiko

Publisher

John Wiley & Sons, Inc.

Reference52 articles.

1. A risk - based approach to immunogenicity concerns of therapeutic protein products. Part 2. Considering host - specific and product - specific factors impacting immunogenicity;Rosenberg;BioPharm Int,2004

2. A risk - based approach to immunogenicity concerns of therapeutic protein products. Part 3. Effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies;Rosenberg;BioPharm Int,2005

3. A risk - based approach to immunogenicity concerns of therapeutic protein products. Part 1. Considering consequences of the immune response to a protein;Worobec;BioPharm Int,2004

4. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction;Koren;Curr Pharm Biotechnol,2002

5. Effects of deleting A19 tyrosine from insulin;Du;Biochem Mol Biol Int,1998

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics;The AAPS Journal;2016-08-05

2. Immunogenicity considerations;Biosimilars and Interchangeable Biologics;2015-12-02

3. Mechanisms Underlying the Immunogenicity of Therapeutic Proteins: Risk Assessment and Management Strategies;Journal of Interferon & Cytokine Research;2014-12

4. Improved analytical methods for the detection and quantification of neutralizing antibodies to biopharmaceuticals;Bioanalysis;2012-09

5. Immunogenicity and other problems associated with the use of biopharmaceuticals;Therapeutic Advances in Drug Safety;2011-05-10